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Background and purpose — In a previous registry report, short-
term implant survival of hip resurfacing arthroplasty (HRA) in 
Finland was found to be comparable to that of total hip arthro-
plasty (THA). Since then, it has become evident that adverse reac-
tions to metal debris (ARMDs) may also be associated with HRA, 
not only with large-diameter head metal-on-metal THA. The aim 
of the study was to assess medium- to long-term survivorship of 
HRA based on the Finnish Arthroplasty Register (FAR). 
Patients and methods — 5,068 HRAs performed during the 
period 2001–2013 in Finland were included. Kaplan-Meier sur-
vival analysis was used to calculate survival probabilities and 
their 95% confi dence intervals (CIs). Cox multiple regression, 
with adjustment for age, sex, diagnosis, femoral head size, and 
hospital volume was used to analyze implant survival of HRA 
devices with revision for any reason as endpoint. The reference 
group consisted of 6,485 uncemented Vision/Bimetric and ABG II 
THAs performed in Finland over the same time period.
Results — The 8-year survival, with any revision as an end-
point, was 93% (CI: 92–94) for Birmingham Hip Resurfacing 
(BHR), 86% (CI: 78–94) for Corin, 91% (CI: 89–94) for ReCap, 
92% (CI: 89–96) for Durom, and was 72% (CI: 69–76) for the 
Articular Surface Replacement (ASR). The 10-year survival, with 
any revision as an endpoint, for reference THAs was 92% (CI: 
91–92) and for all HRAs it was 86% (CI: 84–87%). Female HRA 
patients had about twice the revision risk of male patients. ASR 
had an inferior outcome: the revision risk was 4-fold higher than 
for BHR, the reference implant. 
Interpretation — The 10-year implant survival of HRAs is 86% 
in Finland. According to new recommendations from NICE (The 
National Institute for Health and Care Excellence), an HRA/THA 
should have a revision rate of 5% or less at 10 years. None of the 
HRAs studied achieved this goal.
■
Metal-on-metal hip resurfacing arthroplasty (HRA) has 
theoretical advantages over total hip arthroplasty (THA) for 
younger patients: bone stock preservation on the femoral 
side, more physiological loading of the proximal femur, and 
a low risk of dislocation due to the large head. It has, how-
ever, become evident that adverse reactions to metal debris 
(ARMDs) may often be associated with HRA also, not only 
with large-diameter head metal-on-metal THA. The Articular 
Surface Replacement HRA (ASR; DePuy, Leeds, UK) and the 
Durom HRA (Zimmer, Warsaw, IN) have been recalled from 
the market due to a high prevalence of ARMDs and a high 
early revision rate. Other HRA devices have had variable suc-
cess. The survival rate of the Birmingham Hip Resurfacing 
(BHR) (Smith and Nephew, Warwick, UK) has been higher 
than that of all other HRA devices, according to reports from 
national registries (AOANJRR, NJR, NZJR). 
According to a previous report from the Finnish Arthro-
plasty Register (FAR) with data from 2001 to 2009 (Seppänen 
et al. 2012), 8-year implant survival of HRA in Finland was 
comparable to that of THA. Lately, however, a prevalence of 
ARMD of no less than 7% in male patients and 9% in female 
patients has been reported for BHR at 10 years (Reito et al. 
2014). Disconcertingly, Bisschop et al. (2013) reported a 28% 
prevalence of CT-verifi ed pseudotumors for BHR by 3 years. 
Junnila et al. (2015) reported 17 ARMD cases in 42 BHR hips 
diagnosed with MRI and blood ion measurements, 7 years 
after the hip arthroplasty; 4 hips had been revised. 
It has recently been stated that the routine use of HRA may 
not be justifi ed (Dunbar et al. 2014). In addition, resurfacing 
components are more costly and do not provide any additional 
benefi t over THA, even for younger patients (Jameson et al. 
2015). As early as May 2012, the Finnish Arthroplasty Soci-
ety recommended that MoM HRAs should no longer be used 
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(FAA 2012). A nationwide screening of all MoM HRA and 
THA patients was started. The screening involved patient-
reported outcome measures (Oxford hip score), blood chro-
mium and cobalt ion measurements, and radiography. This 
report is an update on 8- to 10-year survivorship of HRA with 
FAR data extending from 2001 to 2013. 
Patients and methods
The FAR has collected information on total hip replacements 
since 1980 (Paavolainen et al. 1991). Orthopedic units are 
obliged to provide the Finnish National Institute for Health 
and Welfare with information essential for maintenance of the 
register. Dates of death and dates of individuals leaving the 
country are obtained from Statistics Finland. Data capture of 
the Finnish Arthroplasty Register is high when compared to 
the Discharge Register (www.thl.fi /far). An English transla-
tion of the FAR notifi cation form has been published (Puo-
lakka et al. 2001). From May 19, 2014, all hip and knee data 
have been recorded electronically based on bar-code reading.
6 HRA designs used in at least 100 operations during the 
study period 2001–2013 were included (Table 1). There were 
5,068 HRAs altogether, of which 4,474 (88%) were performed 
for primary osteoarthritis, 323 (6.4%) for secondary osteoar-
thritis, 47 (0.9%) for rheumatoid arthritis, 26 (0.5%) for other 
infl ammatory arthritis, 68 (1.3%) for congenital dislocation of 
the hip, and 130 (2.6%) for other indications. The reference 
group consisted of 6,485 uncemented Vision/Bimetric THAs 
(Biomet, Warsaw, IN) and ABG II THAs (Stryker, Mahwah, 
NJ) THAs performed in the same time period. Demographic 
data are presented in Table 2 and the indications for revision 
are given in Table 3.
Statistics
The survival of the HRA devices and the reference arthroplas-
ties was assessed by Kaplan-Meier analysis. The Cox multiple 
regression model was used to assess differences in revision 
rates of the HRA devices and to adjust for any confound-
ing factors. Revisions were linked to the primary operation 
through the personal identifi cation number. The survival end-
point was defi ned as revision, when either 1 of the components 
or the entire implant was removed or exchanged. Revision for 
any reason served as an endpoint. Kaplan-Meier survival data 
were used to construct the survival probabilities of implants, 
with 95% confi dence interval (CI). HRA and THA devices of 
patients who died or left Finland during the follow-up period 
were regarded as having survived until that point. The fac-
tors studied with the Cox model were HRA device, age group, 
sex, diagnosis, femoral head size (classifi ed as ≤ 44 mm, 
45–49 mm, 50–54 mm, and ≥ 55 mm) and hospital production 
volume of arthroplasties (≥ 100 or < 100 procedures). 
The Cox analysis between the whole HRA group and the 
reference THA group showed that these factors were not 
useful. The sizes of the femoral heads of the reference THA 
group were smaller than those of the HRA group. Diagnosis 
and hospital volume had no effect and were censored. Female 
sex had no effect in the reference THA group, but the effect in 
the HRA group was strong and negative. Several age groups 
were tested, but age did not emerge as a signifi cant factor in 
either group. After careful analysis, we decided to compare 
the HRA group and the reference group without consideration 
of these potentially confounding factors. 
The proportional-hazards assumption of the Cox models 
was checked by inspecting the corresponding log-log graphs. 
For Cox analyses comparing the HRA brands and the refer-
ence THA group, we divided the total follow-up time into 3 
periods (fi rst year, second and third year combined, and fourth 
year onwards), because the proportional-hazards assumption 
was not fulfi lled for the total follow-up, as can be seen from 
Figure 1.
Death of the patient and revision are competing risk in reg-
istry studies. We therefore repeated the analyses without the 
patients who died during follow-up (3.2% in the HRA group 
and 14% in the THA group) (Appendix 1, see Supplementary 
data). Furthermore, we performed competing risk analyses 
using Stata 14 statistical software (Appendix 2, see Supple-
mentary data). 
Inclusion of bilateral cases in a survival analysis violates 
the basic assumption that all cases are independent. However, 
several reports have shown that the effect of including bilat-
eral cases in studies of hip and knee joint prosthesis survival, 
Table 1. HRA designs used in  100 
operations during the period 2001–
2013 in Finland









Table 2. Demographic data for hip resurfacing arthroplasty (HRA) 
and total hip arthroplasty (THA), which was used for reference
 HRA reference THA
 n = 5,068 n = 6,485
Mean follow-up (range), years 6.8 (0.0–12.7) 7.9 (0.0–13.0)
Median follow-up, years 7.0 8.8
Mean age (range), years 54 (9–86) 64 (15–97)
Males, % 67 46 
Implanting period 2001–2013 2001–2013
No. of hospitals 49 65
Diagnosis, % primary osteoarthritis 88 84
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as done in our study, is negligible (Lie et al. 2004, Robertsson 
and Ranstam 2003). The Wald test was used to test the esti-
mated hazard ratios. Differences between groups were consid-
ered to be statistically signifi cant if the p-values were less than 
0.05 in a 2-tailed test.
Results
67% of the HRA patients were male, and the mean age of the 
study population was 54 (9–86) years. Primary osteoarthritis 
was the most common diagnosis (88%) (Table 2). The main 
reason for revision of HRAs was aseptic loosening of both 
components (40%), whereas THAs were most often revised 
due to dislocation (26%). Unspecifi ed reasons for revision 
(“other”) were recorded for 24% of the HRA revisions and for 
10% of the THA revisions (Table 3). 
The 10-year Kaplan-Meier survival was 86% (CI: 84–87) 
for the HRA group and 92% (CI: 91–92) for the reference 
THA group (Figure 1 and Table 4). 
The ASR was associated with a higher risk of revision than 
the BHR (revision ratio (RR) = 4.0, CI: 3.2–4.9; p < 0.001) 
(Table 5). The CIs for the BHR, Durom, ReCap, Converse 
Plus, and Corin designs overlapped considerably, and the 
analysis does not permit ranking among them.
Table 3. Reasons for revision. Values are n (%)
 HRA reference THA
Reason for revision n = 5,068 n = 6,485
Aseptic loosening of 
 both components 215 (40) 96 (19)
 the cup 53 (10) 22 (4)
 the stem 18 (3) 23 (4)
Infection 17 (3) 33 (7)
Dislocation 6 (1) 132 (26)
Malposition 45 (8) 49 (10)
Fracture 49 (9) 85 (17)
Implant breakage 3 (1) 18 (4)
Other reason a 131 (24) 49 (10)
All  537 507
a Including ARMD (adverse reaction to metal debris).
Figure 1. Kaplan-Meier survival of HRA and uncemented reference 












0 1 2 3 4 5 6 7 8 9 10 11 12 
Survival proportion (%) 




Table 4. Survival of HRA devices and the reference THA group. Endpoint was defi ned as revision of any component for any reason. 
Survival rates according to Kaplan-Meier analysis 
 n Follow-up, years At risk,  5-year survival At risk,  8-year survival At risk,  10-year survival
  mean (range) 5 years (95% CI) 8 years (95% CI) 10 years (95% CI)
BHR 2,141 7.6 (0.0–12.7) 1,703 96 (95–97) 1,146 93 (92–94) 698 91 (89–92)
ASR 1,051 6.5 (0.0–9.8) 864 88 (86–90) 253 72 (69–76) 0 –
ReCap 846 5.5 (0.0–9.7) 546 94 (93–96) 183 91 (89–94) 0 –
Conserve Plus 579 5.3 (0.0–8.7) 428 95 (93–97) 6 – 0 –
Durom 350 6.9 (0.0–9.1) 326 95 (93–98) 103 92 (89–96) 0 –
Corin (Cormet) 101 9.1 (0.7–11.6) 95 94 (89–99) 72 92 (87–97) 46 86 (78–94)
All HRAs  5,086 6.8 (0.0–12.7)  3,848 94 (93–94) 1,724 88 (87–89) 701 86 (84–87)
Reference THAs 6,485 7.9 (0.0–13.0)  4,801 94 (94–95) 3,711 93 (92–94) 2,402 92 (91–92)
Table 5. Revision ratios (RRs) with 95% confi dence intervals (CIs) 
for HRA devices compared to BHR. Data are based on a Cox 
regression model including implant design, sex, and femoral head 
diameter (categorized as  44 mm, 45–49 mm, 50–54 mm, and  55 
mm). Age group, hospital volume ( 100 or < 100 procedures) and 
diagnosis had no signifi cant effect on adjustment (data not shown) 
 RR 95% CI of RR   p-value
BHR (reference) 1.00 
Cormet 1.05 0.59–1.87 0.9
ASR 3.96 3.20–4.91 < 0.001
ReCap 1.21 0.88–1.67 0.2
Durom 1.02 0.65–1.58 0.9
Conserve Plus 1.30 0.90–1.88 0.2
Female (male reference) 2.12 1.66–2.70 < 0.001
Femoral head diameter, mm
 < 44 (reference) 1.00 
 45–49 0.70 0.54–0.92 0.01
 50–54 0.61 0.44–0.85 0.003
 ≥ 55 0.46 0.27–0.77 0.003
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Female patients had about twice the revision risk of male 
patients (RR = 2.1, CI: 1.7–2.7; p < 0.001). A femoral head 
diameter of less than 44 mm was independently associated 
with a higher revision risk (Table 5). 
BHR and ASR were associated with a lower revision risk 
than the reference THA during the fi rst postoperative year. 
During the second and third postoperative years, ASR was 
associated with a higher revision risk than the reference THA. 
During follow-up from the fourth postoperative year onwards, 
BHR, Cormet, ASR, ReCap, and Converse Plus were associ-
ated with a higher risk of revision than the reference THA 
(Table 6).
The revision ratios at different follow-up time intervals for 
6 HRA devices compared to uncemented reference THA—
and with dead patients excluded—are presented in Appendix 
1. The RRs from the fourth postoperative year onwards for 
6 HRA devices compared to uncemented reference THA, 
and with death as competing risk, are presented in Appendix 
2. Revision rate of all 6 HRA devices is increased from the 
fourth year onwards (Appendices, see Supplementary data).
Discussion
The 10-year implant survival of HRAs is 86% in Finland. The 
10-year survival of the BHR in Finland is similar to that in 
England and Wales (91%). According to the current NICE rec-
ommendations, the revision rate of HRAs/THAs should be no 
higher than 5% by 10 years. None of the HRAs in this study 
achieved this goal. 
The cumulative rate of revision of all HRAs by 10 years in 
Australia was 9.8%, and that of conventional THAs was 6.8% 
(AOANJRR). The cumulative rate of revision of all HRAs by 
10 years in England and Wales (NJR) was 13%, and that of 
uncemented THAs was 7.7%. Our data support these fi ndings: 
the overall long-term survival of conventional THAs is higher 
than that of HRAs. Lately, it has been stated, based on the NJR 
data, that there is no advantage in using resurfacing implants 
over THA, even in young patients (Jameson et al. 2015). In 
a previous report based on data from 2001–2009 (Seppänen 
et al. 2012), we concluded that HRA had comparable 4- to 
8-year survivorship to that of THA at the national level. It is 
now evident that this conclusion was not valid in 8- to 10-year 
follow-up. 
The 10-year cumulative rate of revision of the BHR is 6.9% 
in Australia (AOANJRR) and 9.0% in England and Wales 
(NJR). Our registry results on BHR are similar. Excellent 
implant survival results have been published for the BHR based 
on data from single centers. 10-year survival rates as high as 
97%, 15-year survival rates of 96% (Daniel et al. 2014), and 
10-year survival rates of 96% (Matharu et al. 2013) have been 
reported by the design center. An overall 13-year survival rate 
of 92% was reported for the BHR by van der Straeten et al. 
(2013) based on independent single-center data. The 10-year 
overall survival rates based on independent single centers have 
varied between 87% and 95% (Coulter et al. 2012, Holland 
et al. 2012, Murray et al. 2012, Reito et al. 2014). However, 
survival rates have constantly been worse for female patients, 
with 10-year survival rates of no more than 67% for women in 
younger age groups (Murray et al. 2012). 
There has been concern about local adverse tissue reac-
tions associated with the use of the BHR, as with other HRA 
devices. An ARMD prevalence of 6.9% in male patients and 
8.8% in female patients has been reported for the BHR (Reito 
et al. 2014). Bisschop et al. (2013) reported a 28% prevalence 
of CT-verifi ed pseudotumors in BHR patients by 3 years. In 
the current study, the revision risk for BHR was similar to 
that for other HRA devices except ASR. The revision risk for 
the BHR compared to uncemented THAs increases from the 
fourth postoperative year onward. The survival rate of BHRs 
beyond 10 years may deteriorate further compared to conven-
tional THAs due to revisions indicated by ARMD. 
The 7-year cumulative rate of revision of the ASR was 24% 
in Australia (AOANJRR) and the 10-year rate was 30% in 
England and Wales (NJR). These results are in line with ours. 
ASR was recalled by the manufacturer in September, 2010. 
An 8-year implant survival of 96% with revision for any 
reason as endpoint was reported from single-center data by 
Vendittoli et al. (2013) for the Durom HRA. This extraordi-
nary fi nding has not been verifi ed in population-based registry 
Table 6. Revision ratios (RRs) with 95% confi dence intervals (CIs) in 6 HRA devices compared to the uncemented reference 
THA. Data are based on a Cox regression model at different follow-up time intervals (the fi rst year, the second and third years, 
and from the fourth year onwards)
 Follow-up interval: 1st year Follow-up interval: 2nd and 3rd  year  Follow-up: from 4th year onwards
 RR 95% CI for RR p-value RR 95% CI for RR p-value RR 95% CI for RR p-value
Reference THA 1   1   1   
BHR 0.48 0.32–0.70 0.0002 0.83 0.54–1.26 0.4 1.66 1.31–2.11 < 0.001
Cormet 0.67 0.17–2.70 0.6 1.84 0.58–5.81 0.3 2.06 1.02–4.18 0.04
ASR 0.58 0.36–0.94 0.03 1.85 1.24–2.77 0.003 9.18 7.44–11.31 < 0.001
ReCap 0.64 0.38–1.07 0.09 0.82 0.44–1.53 0.5 2.30 1.55–3.42 < 0.001
Durom 0.58 0.26–1.31 0.2 1.44 0.70–2.95 0.3 1.15 0.59–2.25 0.7
Conserve Plus 1.00 0.61–1.64 1.0 0.78 0.36–1.68 0.5 1.78 1.03–3.08 0.04
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studies. The 10-year cumulative rate of revision of the Durom 
was 10% in Australia (AOANJRR) and 9.4% in England and 
Wales (NJR). These data are in accordance with our results 
(8% at 8 years). Durom was recalled by the manufacturer 
2008 due to high early revision rates.
An 11-year implant survival of 93% with revision for any 
reason as endpoint was reported from single-center data by 
Gross et al. (2012) for the Corin Cormet HRA. The cumu-
lative revision rate for adverse wear failure was 1% (Gross 
and Liu 2013). The 10-year cumulative rate of revision of the 
Corin Cormet HRA was 19% in both Australia (AOANJRR) 
and England and Wales (NJR). Our results (14% at 10 years) 
are in accordance with these population-based fi ndings.
According to single-center data, the implant survival rate of 
the ReCap HRA is 94% over 6 years (van der Weegen et al. 
2012), 96% over 7 years (Gross and Liu 2012), and 100% over 
7 years (Borgwardt et al. 2015). The 7-year cumulative per-
cent probability of revision of the ReCap was 12% in Austra-
lia (AOANJRR) and 9% in England and Wales (NJR). Again, 
our results (9% at 8 years) are in accordance with previous 
population-based fi ndings.
5-year survival rates of 98% (Amstutz et al. 2007) and 95% 
(Zylberberg et al. 2015) have been reported for the Conserve 
Plus HRA, based on single-center data. The 10-year survival 
rate of the Conserve Plus cup was 98% with aseptic loosening 
as the endpoint (Hulst et al. 2011) and 89% for the Converse 
Plus HRA with revision for any reason as endpoint (Amstutz 
et al. 2010). The 10-year cumulative rate of revision of the 
Conserve Plus was 14% in England and Wales (NJR). In Fin-
land, the Conserve Plus HRA is not in common use and fol-
low-up times are short, but we did fi nd a 5-year survival rate 
for the Converse Plus of 95%, which is comparable to that of 
other HRA devices. 
In the current report, as well as in the previous one, aseptic 
loosening was the most common reason for revision—53% 
and 51%, respectively (Seppänen et al. 2012). The most 
common reason for HRA revision in Australia has been 
loosening/lysis (33%), followed by metal-related pathology 
(24%), and fracture (21%) (AOANJRR). In England and 
Wales, the most common reason for HRA revision was pain, 
followed by aseptic loosening and other indications (NJR). 
The variation in indications for revisions between registries 
indicates that the defi nitions of the indications are ambigu-
ous. Pain only or ARMD were not coded as reasons for revi-
sion in the previous pre-registry notifi cation form of the FAR. 
Revisions performed for ARMD were coded as performed for 
“other reason”. There were 131 HRA revisions (24% of all 
revisions) performed for “other reason” in the current study, 
compared to 8% in the previous report (Seppänen et al. 2012). 
These data have been available after the reformation of the 
registry on May 19, 2014. 
The revision rate in women has reportedly been about twice 
that in men (AOANJRR, NJR). However, based on data from 
the Australian registry, adjustment for femoral head size elim-
inates female sex as an independent risk factor (Prosser et al. 
2010). On the other hand, the NARA group found that femo-
ral head diameter alone had no effect on the early revision 
rate (Johanson et al. 2010). We found that the HRA revision 
rate for women is twice as high as for men. We also found a 
higher risk of revision in the group with the smallest femoral 
head diameter. Perhaps somewhat surprisingly, a high hospital 
production volume was not associated with reduced risk of 
revision. 
Since our study design was observational, it was vulner-
able to omission of variables, which may have confounded 
our fi ndings. Potentially important variables such as comor-
bidity and socioeconomic status were not available. In addi-
tion, important clinical information (such as radiological data, 
patient-reported outcome measure data, and data on blood 
metal ion concentrations) was not available. 
Supplementary data
Appendix 1 and 2, are available on the website of Acta Ortho-
paedica (www.actaorthop.org), identifi cation number 9663.
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